Blinatumomab: Cytokine release syndrome.

Author InformationAn event is serious (based on the ICH definition) when the patient outcome is:• * death * life-threatening * hospitalisation * disability * congenital anomaly * other medically important eventIn a single-center, retrospective, real-world, cohort study involving 34·patients treated with blinatumomab between between 30·October·2018 and 1·December·2021, et al. patient [age and sex not stated] was described, who developed cytokine release syndrome (CRS) following treatment with blinatumomab for minimal residual disease (MRD)-positive acute lymphoblastic leukaemia (ALL) [route and dosage not stated]. [Extracted from the article]